•
Jul 03, 2021

Perrigo Q2 2021 Earnings Report

Perrigo's Q2 2021 financial results from continuing operations were reported.

Key Takeaways

Perrigo's Q2 2021 net sales increased by 3.4% to $981 million, driven by growth in most businesses and favorable currency movements, but adjusted EPS decreased by 15.3% to $0.50 due to reinstatement of brand and marketing investments.

Perrigo reaffirmed its fiscal 2021 net sales guidance.

Adjusted EPS is now expected towards the lower end of the guidance range due to lower sales volumes and higher input costs.

U.S. and E.U. Consumer Self-Care Take Away Rebounded Sharply in the Quarter.

Divestiture of RX Business for $1.55 Billion Completed on July 6, 2021, Providing Significant Cash for Driving Business Growth.

Total Revenue
$981M
Previous year: $1.22B
-19.5%
EPS
$0.5
Previous year: $1.03
-51.5%
Adjusted Operating Income
$118M
Previous year: $200M
-41.3%
Gross Profit
$349M
Previous year: $435M
-19.7%
Cash and Equivalents
$318M
Previous year: $1.46B
-78.2%
Free Cash Flow
-$105M
Previous year: $265M
-139.8%
Total Assets
$11.2B
Previous year: $12.1B
-7.4%

Perrigo

Perrigo

Perrigo Revenue by Segment

Forward Guidance

The Company reaffirmed its fiscal 2021 organic net sales growth outlook of 3% and now expects adjusted diluted EPS towards the lower end of its adjusted diluted EPS range of $2.50 to $2.70.

Revenue & Expenses

Visualization of income flow from segment revenue to net income